Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly

  • Fritsch K
  • Kasenda B
  • Hader C
 et al. 
  • 33


    Mendeley users who have this article in their library.
  • 60


    Citations of this article.


Primary central nervous system lymphoma (PCNSL) is an aggressive extranodal non-Hodgkin lymphoma confined to the central nervous system. In this article, we report the results of a pilot trial adding rituximab to the established regimen consisting of methotrexate, procarbazine, and lomustine (R-MCP). Design and methods: PCNSL patients ≥65 years without Karnofsky performance score (KPS) limit were included. R-MCP regimen consisted of rituximab (375 mg/m(2) i.v. on days -6, 1, 15, and 29), methotrexate (3 g/m(2) i.v., days 2, 16, and 30) followed by folinic rescue, procarbazine (60 mg/m(2) orally, days 2-11), and lomustine (110 mg/m(2) orally, day 2). A maximum of three 43-day cycles were applied. Primary end point was response to treatment obtained by magnetic resonance imaging. Secondary end points were overall survival (OS) and progression-free survival (PFS).

Author-supplied keywords

  • Elderly
  • High-dose MTX
  • Non-Hodgkin lymphoma
  • Rituximab

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • K. Fritsch

  • B. Kasenda

  • C. Hader

  • G. Nikkhah

  • M. Prinz

  • V. Haug

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free